Form 483

Hahnemann Laboratories, Inc. dba Alpine Pharmaceuticals Form 483, 2020-01-28

FDA issued a Form 483 to Hahnemann Laboratories, Inc. dba Alpine Pharmaceuticals on 2020-01-28 with 5 public-safe observations.

483· Form 483 issuedHuman Drugs5 observations

Hahnemann Laboratories, Inc. dba Alpine Pharmaceuticals · San Rafael, United States · Issued January 28, 2020

Overview

  • 5 public-safe observations are available for this inspection.
  • 5 structured CFR citations are represented.
  • 1 investigator is tied to this Form 483.

Inspectional observations

Each observation cites the regulation FDA found the firm out of compliance with.

28 Jan 2020
21 CFR 211.165(e)

Test methods

Cited by Jolanna A Norton

28 Jan 2020
21 CFR 211.22(d)

Procedures not in writing, fully followed

Cited by Jolanna A Norton

28 Jan 2020
21 CFR 211.25(a)

Training--operations, GMPs, written procedures

Cited by Jolanna A Norton

28 Jan 2020
21 CFR 211.84(d)(2)

Establish reliability of supplier's C of A

Cited by Jolanna A Norton

28 Jan 2020
21 CFR 211.84(e)

Rejecting When Specifications Not Met

Cited by Jolanna A Norton

Inspected site

Inspection team

Cited regulations

CFR citations associated with this Form 483.

CitationWhat it coversCited
21 CFR 211.165(e)Cited across public-safe Form 483 observations1x
21 CFR 211.22(d)Cited across public-safe Form 483 observations1x
21 CFR 211.25(a)Cited across public-safe Form 483 observations1x
21 CFR 211.84(d)(2)Cited across public-safe Form 483 observations1x
21 CFR 211.84(e)Cited across public-safe Form 483 observations1x

Source document

PDF
PDF available

Form 483 source document

The source document is available to authorized Atlas users.

Full 483 report

Get the verbatim text of all 5 observations

The source PDF, so your team sees exactly what was cited and how it was answered.

  • The site's full inspection history around this Form 483
  • Whether these citations escalated to a warning letter
  • The investigators involved and the citations they repeat elsewhere